GLP1R and obesity due to melanocortin 4 receptor deficiency: Emerging obesity medicine (obesitology) provides additional therapeutic options, including pharmacological interventions (e.g., GLP-1 receptor agonists such as semaglutide, or agents like bupropion for patients with emotional eating patterns) and bariatric surgery for eligible individuals [7,15].